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Intrathecal reboxetine suppresses evoked and
ongoing neuropathic pain behaviours by restoring
spinal noradrenergic inhibitory tone
Sam Hughesa, Louise Hickeya, Lucy F. Donaldsonb, Bridget M. Lumba,*, Anthony E. Pickeringa
Abstract
The descending noradrenergic (NAergic) projection to the spinal cord forms part of an endogenous analgesic system. After nerve injury,
a localised failure in this compensatory system has been implicated as a permissive factor in the development of neuropathic sensitisation.
We investigated whether restoring descending NAergic tone with intrathecal reboxetine can oppose the development of the neuropathic
pain phenotype after tibial nerve transection (TNT). Rats had a lumbar intrathecal catheter implanted at the time of nerve injury for
administration of reboxetine (10 mg) in both acute and chronic dosing experiments. In acute dosing experiments, both intrathecal and
systemic (30 mg/kg) reboxetine partially reversed mechanical allodynia. This antiallodynic effect of intrathecal reboxetine was blocked by
prior administration of yohimbine (a2-adrenoceptor antagonist, 30 mg) but not by prazosin (a1-adrenoceptor antagonist, 30 mg) or
propranolol (b-adrenoceptor antagonist, 100mg). Chronic intrathecal reboxetine (10 mg, intrathecally, twice daily for 2 weeks) suppressed
the development of cold and mechanical allodynia. Nerve-injured animals demonstrated a place preference for intrathecal reboxetine,
suggesting that it also reduced spontaneous pain. In contrast, an equivalent antiallodynic dose of systemic reboxetine (30 mg/kg) was
aversive in both naive and TNT rats. On cessation of chronic intrathecal reboxetine, there was a gradual development of allodynic
sensitisation thatwas indistinguishable fromcontrol TNTanimalsby7daysafter theendofdosing.Our results suggest that pharmacological
restoration of spinal NAergic tone with intrathecal reboxetine can suppress both allodynia and spontaneous pain in the TNT model.
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1. Introduction
Neuropathicpain arisingafter a lesion of a peripheral nerve results in
the development of increased sensitivity to applied stimuli and/or
spontaneous ongoing pain. Treatment options for such neuro-
pathic pain remain limited,15 but noradrenergic (NAergic) reuptake
inhibitors are among the most clinically effective agents.4,41
However, their utility is often limited by troublesome side effects
that follow systemic administration as a result of both on- and off-
target actions.41 Therefore, there has been considerable interest in
dissecting themechanismof actionof the central NAergic system in
pain control, particularly during the development of neuropathic
sensitisation, with a view to identify better means of therapeutic
intervention.32,38
A population of pontine NAergic neurons with descending
projections to the spinal cord is thought to regulate acute pain
processing.22,23,26,49 After peripheral nerve injury, changes within
this descending NAergic control system have been implicated in
the development of neuropathic pain.19,25,39,46 Intriguingly, differ-
ences in the ability to engage this NAergic control system have
been linked to the variable expression of neuropathic sensitisation
in several nerve-injury models and across rat strains.9,50 The
descending NAergic system acts to delay the appearance of
neuropathic signs in the acute phase after nerve injury but then fails
to prevent the onset of sensitisation because of a progressive loss
of spinal NAergic tone,24 although it still acts to spatially limit the
spread of sensitisation from the injured nerve territory.
Strategies to augment NAergic tone through the use of reuptake
inhibitors have been partially effective in alleviating neuropathic
allodynia in experimental models when administered system-
ically5,6,14 and also when given intrathecally (i.t.).36 This latter
approach is of particular interest becausemany of the troublesome
side effects of the reuptake inhibitors (such as sedation, dizziness,
and anxiety) are thought to be mediated at supratentorial sites,
which could be minimised by intrathecal dosing. However,
effectiveness of chronic intrathecal administration of a selective
NAergic reuptake inhibitor on the development of neuropathic pain
has yet to be explored.
Given that there is evidence for a loss of descending spinal
NAergic tone after nerve injury, we aimed to test the efficacy of
chronic dosing with spinal reboxetine (selective reuptake inhibitor)
to see whether it could prevent or attenuate the development of
neuropathic sensitisation. We show that intrathecal reboxetine
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acts to effectively suppress neuropathic sensitisation through an
a2-mediated mechanism. Furthermore, we show that intrathecal
reboxetine induces a place preference in nerve-injured (but not
naive) animals, suggesting that it attenuates ongoing spontaneous
pain,27 whereas an equivalently effective antiallodynic dose of
systemic reboxetine produces aversion in both tibial nerve
transection (TNT) and naive animals.
2. Materials and methods
2.1. Animals
Experiments were performed onmaleWistar rats (n5 55; Harlan,
Bicester, United Kingdom). All procedures were licenced by the
UK Home Office according to the 2010/63 Directive of European
Union and adhered to the guidelines of the Committee for
Research and Ethical Issues of International Association for the
Study of Pain. All experimental protocols were approved by the
University of Bristol local Ethical Review Panel. Animals were
single housed, with an enriched environment under a standard
12-hour light–dark cycle, with ad libitum access to food and
water.
2.2. Tibial nerve transection model
Peripheral neuropathy was induced using the TNT variant of the
spared nerve-injury (SNI) model (n 5 38).24,28 Under ketamine
(50 mg/kg) and medetomidine (300 mg/kg) anaesthesia, the left
hind limb was abducted and externally rotated to a lateral
position, and a longitudinal incision was made at the mid-thigh
level through the biceps femoris. The sciatic nerve was exposed
and the sural, tibial, and common peroneal branches were
carefully identified. The tibial nerve was tightly ligated with 5-0 silk
and a 2-mm section was cut, taking care to avoid damage to the
sural and common peroneal nerves.
2.3. Chronic intrathecal cannulation
A chronic intrathecal catheter was implanted at the L5-L6
interspace24,42,45 at the same time as TNT (n 5 26, under
continuous anaesthesia) and also in naive rats (n 5 10). A
sterilised 32-gauge intrathecal catheter (CR3212; ReCathCo;
Allison park, PA) was threaded through a 25-gauge hypodermic
needle inserted between L5-L6 vertebrae until a tail flick indicated
penetration of the dura. The catheter was advanced cranially 2 to
3 cm so the rostral tip reached the lumbar enlargement. The
needle and catheter stylet were removed, and the catheter was
joined to an 8-cm length of PE-10 tubing, which was sutured to
the paraspinous muscle and tunnelled subcutaneously to the
level of the scapulae. The catheter was externalised by attaching
the PE-10 tubing to a 2-cm length of PE-50 tubing that was fixed to
a back-mounted pedestal system with a screw cap (313-000BM-
10-SP with 6-mm side connector; Plastics One, Roanoke, VA). All
intrathecal drug injections were made in a volume of 10 mL using
a 50 mL Hamilton syringe at a rate of;0.5 mL per second followed
by a 17 mL dead space flush with saline. Correct cannula
placement was confirmed by rapid and reversible hind limb
paralysis after a 20 mL intrathecal lidocaine injection (10 mg/mL) at
the end of the behavioural testing protocol.
2.4. Nociceptive testing
2.4.1. Mechanical allodynia
The hind paw withdrawal thresholds to tactile stimuli were
assessed using calibrated von Frey filaments ranging from 0.17 to
26.0 g (TouchTest, Linton Instrumentation, Diss, United King-
dom). Briefly, rats were placed in Perspex chambers with a metal
mesh floor and were allowed to habituate for 15 minutes before
behavioural testing. Testing started with the 2.0 g von Frey
filament, applied perpendicular to the plantar surface of the hind
paw for 3 seconds. Withdrawal thresholds were assessed and
quantified using the Dixon up-and-down method.7
2.4.2. Cold allodynia
Hind pawwithdrawal responses to cooling stimuli were assessed
using the acetone test.8 After habituation to the chamber, a 1 mL
syringe was used to apply a drop of acetone through the mesh
floor to the plantar surface of the hind paw, and a hindlimb
withdrawal was scored as a positive response. Acetone testing
was repeated 5 times per paw with a 2-minute interval between
tests, and data are represented as percentage paw withdrawal
frequency recorded in response to 5 acetone applications (PWF).
2.5. Experimental protocols
2.5.1. Comparison of acute intrathecal and systemic
reboxetine on mechanical allodynia
TNT rats developed mechanical allodynia over a 10-day period.
On day 10, nerve-injured (n 5 5) and naive (n 5 5) rats received
a single intrathecal dose of reboxetine (10 mg)37 or saline
(observer blinded), and the effects on mechanical allodynia were
recorded at 5, 10, 30, 60, 180, 300, 360 minutes and 24 hours
after dosing.
For comparison, in an additional group of TNT rats (n5 5), the
effects of systemic reboxetine on mechanical allodynia were
assayed at the same time points by intraperitoneal (i.p.)
administration on day 10 (1 mg/kg), 12 (10 mg/kg), and 14
(30 mg/kg) each in a volume of 0.1 mL/100 g.29 In each case, the
degree of sensitisation returned to its previous levels 24 hours
after either intrathecal or systemic dosing.
2.5.2. Chronic intrathecal reboxetine administration in tibial
nerve transection rats
Two groups of animals (n 5 5 per group) had TNT surgery and
implantation of chronic intrathecal catheters. Reboxetine (10 mg,
i.t.) or saline was given (observer blinded) at the time of nerve
injury and then every day at 9 AM and 4 PM until day 15 after TNT.
Mechanical and cold nociceptive testing was performed every 3
days beginning at 2 PM until day 25 after TNT.
2.5.3. Role of spinal adrenoceptors inmediating the action of
intrathecal reboxetine
TNT rats (n 5 6) received an intrathecal dose of a selective
adrenoceptor antagonist 5 minutes before reboxetine (10 mg, i.t.).
The testing schedule was performed over a 6-day period with
reboxetine given alone on day 8 and then with intrathecal
yohimbine9,24,43 (a2-AR antagonist, 30 mg in 10 mL 20% DMSO;
Tocris,UnitedKingdom)coadministrationonday10,prazosin (a1-AR
antagonist, 30 mg in 10 mL 30% DMSO; Tocris24,43) on day 12,
propranolol (b-AR antagonist, 100 mg in 10 mL saline11) on day 14,
and vehicle (30% DMSO) on day 16 after TNT.
2.5.4. Place preference conditioning: intrathecal vs systemic
reboxetine in tibial nerve transection and naive rats
We sought to gauge the effects of intrathecal and systemic
reboxetine on “on-going” neuropathic pain using a conditioned
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place preference (CPP) paradigm27,44 between days 21 to 25
post-TNT. Comparisons were made between TNT and naive rats
receiving reboxetine either i.t. (through implanted catheters) or i.p.
For testing, rats had a 2 day habituation period in which they were
allowed to explore all 3 chambers (2 conditioning chambers and
a neutral connecting chamber) of the CPP environment for 15
minutes. On day 3 (preconditioning), the animals were allowed to
free roam and the time spent in each chamber was assessed. On
day 4 (conditioning), all rats received an injection of saline and
were immediately placed in one of the pairing chambers (isolated
from the other chambers) for 30 minutes (i.t.) or 45 minutes (i.p.).
Four hours later, rats received an injection of reboxetine (i.t.,
10 mg or i.p., 30 mg/kg) and were immediately placed in the
opposite chamber for either 30 (i.t.) or 45 (i.p.) minutes. On day 5
(post-conditioning), rats were placed in the CPP box with
freedom to roam between the chambers and the amount of time
spent in the saline- and reboxetine-paired chambers was
recorded over a 15-minute period.
3. Statistical analysis
The presence of sensitisation was indicated by reduction in the
evoked response threshold when compared with pre-TNT or
predrug baseline values, respectively, using a repeatedmeasures
1-way analysis of variance (ANOVA) with Dunnett multiple
comparison post hoc test. Differences between treatment groups
over time were determined by 2-way ANOVA with Bonferroni
multiple comparison post-tests. For CPP testing, the preference
for drug was calculated from the time spent in the reboxetine-
paired chamber during test—preconditioning. The preference or
aversion was assessed using a single sample t test (against the
null hypothesis of no change in preference). Statistical analysis
was performed with Prism software (GraphPad Software Inc, La
Jolla, CA) and levels of significance were indicated as *P, 0.05,
**P , 0.01, and ***P , 0.001, NS, not significant. Power
calculations to estimate experimental group sizes based on initial
pilot data were calculated using G*power with a 5 0.05 and b
$ 0.8.
4. Results
4.1. Intrathecal reboxetine attenuates
neuropathic sensitisation
After TNT, rats developed mechanical hyperalgesia (Fig. 1) and
cold allodynia by day 7 to 10, which is consistent with previous
reports.21,24 Single-shot intrathecal administration of reboxetine
(10mg) produced a significant antiallodynic effect in nerve-injured
rats tested 10 days after surgery (mechanical withdrawal
threshold increased from 1.2 6 0.3 g to 5.9 6 1.2 g at 10
minutes after drug administration; n 5 5, P , 0.05; Fig. 1A)
lasting 60minutes. By comparison, systemic reboxetine (1mg/kg
or 10 mg/kg, i.p.) had no significant effect on TNT sensitisation,
however, a dose of 30 mg/kg produced antiallodynic effects
comparable with that seen with intrathecal reboxetine (mechan-
ical withdrawal threshold increased from 0.9 6 0.3 g to 4.7 6
0.9 g at 30 minutes after drug; n 5 5, P , 0.05; Fig. 1B).
4.2. Chronic intrathecal reboxetine suppresses
neuropathic sensitisation
Having noted that acute intrathecal reboxetine administration
produced a reduction in allodynia that was equivalent to a sub-
stantial systemic dose (Fig. 1), we testedwhether repeated chronic
dosing could produce a maintained suppression of sensitisation.
Chronic intrathecal reboxetine administered twice daily from the
time of TNT prevented the development of mechanical allodynia
(withdrawal threshold for the reboxetine group: 13.1 6 1.1 g vs
saline: 0.86 0.5 g, n5 5; P, 0.001; Fig. 2A at day 10) and cold
allodynia (withdrawals for the reboxetine group 32.0% 6 8.0% vs
saline 84.0%6 7.5%, n5 5; P, 0.001; Fig. 2B at day 10). These
antiallodynic actions were maintained during the whole 2-week
dosing schedule.
4.3. Reboxetine reduces neuropathic sensitisation through
spinal a2-adrenoceptors
The identity of the receptor mediating the antiallodynic effects of
intrathecal reboxetine was investigated by spinally coadminister-
ing adrenoceptor antagonists. As previously noted, reboxetine
alone significantly increased themechanical withdrawal threshold
in TNT animals (predrug: 0.5 6 0.1 g vs reboxetine: 6.3 6 1.5 g;
n 5 6, P , 0.001; Fig. 3). However, this effect was significantly
attenuated by prior administration of yohimbine (0.8 6 0.5 g;
n5 6,P, 0.001 comparedwith reboxetine alone; Fig. 3), but not
by prazosin (30mg), propranolol (100mg), or vehicle (30%DMSO)
administered to the same animals, indicating involvement of
spinal a2-adrenoceptors in the action of reboxetine.
Figure 1. Intrathecal reboxetine attenuates mechanical allodynia. After tibial nerve
transection (TNT), animals developed robust mechanical allodynia by day 10. (A),
Intrathecal reboxetine (10 mg) significantly increased mechanical paw withdrawal
thresholds 10minutes after drug administration in TNT rats butwaswithout effect in
naive rats. (B), Systemic reboxetine (30 mg/kg, i.p.) significantly increased
thresholds 30 minutes after drug administration to a level similar to that seen with
the intrathecal dose (lower doses were without a significant effect). Data are
expressed as mean 6 SEM, n 5 5 per group. Comparisons between pre- and
post-reboxetine mechanical withdrawal thresholds were made using a repeated
measures 1-way analysis of variance with Dunnett multiple comparison test (NS,
not significant, *P, 0.05, **P, 0.01).
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4.4. Tibial nerve transection rats exhibit a preference for
intrathecal reboxetine
We used a place preference assay to test whether intrathecal
reboxetine might be acting to suppress ongoing pain in TNT
animals.27 A single dose of intrathecal reboxetine (10mg) induced
place preference in TNT rats with an increase in the time spent in
the reboxetine-paired chamber after conditioning (117 6 38
seconds,P, 0.05; Fig. 4). Importantly, reboxetine did not induce
place preference in naive rats (29 6 26 seconds, NS; Fig. 4).
These data indicate that intrathecal reboxetine alone is not
sufficient to induce place preference in the absence of nerve injury
consistent with the proposition that it is suppressing an ongoing
neuropathic pain state in the TNT rats.
4.5. Systemic reboxetine seems to be aversive in both tibial
nerve transection and naive rats
To compare the effect of systemic reboxetine, we used a similar
CPP protocol with a dose that produced an equivalent degree of
attenuation of evoked withdrawals (30 mg/kg, i.p., Fig. 1B) as the
intrathecal dose (10 mg). Systemic dosing produced the opposite
effect in place preference testing to that seen with intrathecal
administration. In TNT rats, there was a reduction in the amount of
time spent in the reboxetine-paired chamber (2726 29 seconds,
P , 0.05; Fig. 4). This aversive effect of systemic reboxetine was
also seen in naive rats with a reduction in time spent in the
reboxetine-paired chamber during the test day compared with the
preconditioning day (299 6 24 seconds; P , 0.01; Fig. 4).
4.6. Neuropathic sensitisation develops after
reboxetine discontinuation
On discontinuation of the intrathecal reboxetine (after 2 weeks of
twice daily dosing), both mechanical and cold sensitisation
gradually developed in the ipsilateral limb over the next 7 days
(Fig. 5). The mechanical allodynia was apparent from 5 days after
cessation and was indistinguishable from that seen in the control
group by day 8 after reboxetine withdrawal.
5. Discussion
We have investigated the effect of augmenting pontospinal
NAergic tone, using intrathecal dosing of the selective noradren-
aline reuptake inhibitor—reboxetine,16,37 on the development of
the neuropathic pain phenotype after nerve injury. Using
a combination of acute and chronic dosing through implanted
catheters, we have shown that intrathecal reboxetine can
alleviate spontaneous and evoked pain behaviours through
a spinal a2-AR mediated mechanism. These findings support
the idea that after tibial nerve injury, there is a functional deficit in
pontospinal NAergic tone, which can be reversed by chronic
spinal noradrenaline (NA) reuptake inhibition.
The variable expression of a neuropathic pain phenotype
across individual animals after apparently identical nerve injury is
thought to be dependent on the degree of engagement of the
pontospinal NAergic system.50 Differences between rat strains in
the function of this NAergic system has also been suggested to
play an important role in determining whether allodynia develops
after nerve injury.9 A progressive functional and anatomical deficit
Figure 2. Prophylactic intrathecal reboxetine suppresses the development of
neuropathic sensitisation. Tibial nerve transection rats received intrathecal
reboxetine (10 mg) or vehicle (saline) at the time of injury and then twice daily
(9 AM and 4 PM) until day 15 after injury. In vehicle treated rats, mechanical (A)
and cold (B) allodynia developed by day 7 which was not seen in the chronic
reboxetine group. Data are expressed as mean 6 SEM, n 5 5 per group.
Comparisons between reboxetine- and saline-treated rats using 2-way
analysis of variance (ANOVA) with the Bonferroni post-test (***P , 0.001).
The presence of allodynia in either the reboxetine- or saline-treated groups
was determined by comparisons with pre–tibial nerve transection baseline
thresholds or withdrawals using a repeated measures 1-way ANOVA with the
Dunnett multiple comparison test (NS, not significant, ###P , 0.001).
Figure 3. Intrathecal reboxetine acts through an a2-AR mediated
mechanism. Intrathecal reboxetine (10 mg) significantly increased mechan-
ical withdrawal thresholds in tibial nerve transection (TNT) rats. However,
prior administration of yohimbine (a2-AR antagonist, 30 mg) significantly
attenuated this response. Prior administration of prazosin (a1-AR antago-
nist, 30 mg), propranolol (b-AR antagonist, 100 mg), and vehicle (30%
DMSO) were without an effect. Data are expressed as mean 6 SEM, n 5 6
per group. Themechanical sensitivity of TNT rats before and after reboxetine
administration and in combination with intrathecal antagonists was
compared using 2-way analysis of variance with the Bonferroni post-test
(NS, not significant, ***P , 0.001).
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in the descending NAergic system has been found to accompany
the development of allodynia after nerve injury.24 Inhibition of the
descending NAergic system once neuropathic pain has developed
is either ineffective (perhapsbecauseof a floor effect)22,25 or amplifies
the sensitisation.19,24 Therefore, we addressed the question of
whether selective augmentation of spinal NAergic control could be
a useful therapeutic strategy.
Acute intrathecal administration of reboxetine alleviates
evoked hypersensitivity (to an equivalent degree as a substantial
systemic dose), which is in line with previous reports for acute
intrathecal dosing of the conus peptide Xen2174 (selective NET
inhibitor) in the chronic constriction injury model.36 The question
of which spinal adrenoceptors are involved in the antiallodynic
action of systemic monoamine reuptake inhibitors has previously
been addressed with reports supporting a role for a2-AR
35 and
b2-AR.
52 Here, we found that administration of an a2-AR
antagonist given i.t. alongside reboxetine suppressed the
mechanical antiallodynic effect (see also Refs. 36,37) and found
no evidence for a role of either a1- or b-adrenoceptors. This
a2-AR antagonist reversal of reboxetine actions was also seen for
cold allodynia in preliminary experiments (data not shown).
Furthermore, the effect of intrathecal a2-AR antagonists to block
the effect of reboxetine suggests that it is acting to increase spinal
levels of noradrenaline to exert its therapeutic benefit as has been
demonstrated by spinal microdialysis for systemic administration
of both selective (maprotiline) and nonselective noradrenaline
reuptake inhibitors in a nerve-injury model.35
Clinically, patients commonly describe the presence of sponta-
neous pain after nerve injury3; however most preclinical assays
have focussed on evoked pain measures.33 Although the
occurrence of ongoing pain has been suggested to originate from
spontaneous activity in peripheral nociceptors,10 there is evidence
that descending facilitatory pathways play a role in the long-term
maintenance of spontaneous pain.47 Here, we have used CPP
testing, which has been extensively used to investigate the
rewarding or aversive properties of drugs44 to investigate whether
intrathecal reboxetine attenuates spontaneous pain in the TNT
model using a methodology similar to that of King et al.27 Acute
intrathecal reboxetine administration induced CPP in TNT rats but
importantly not in naive animals, indicating that reboxetine is not
rewarding in of itself when administered spinally. Therefore, this
likely indicates the presence of a tonic ongoing level of pain after
tibial nerve injury that can be alleviated by restoring pontospinal
NAergic inhibition—consistent with the proposition that loss of
descending NAergic control plays a role in the maintenance of
spontaneous neuropathic pain. This is in line with a recent finding
that intrathecal a2-AR agonism with clonidine can also produce
place preference in nerve-injured animals.48 Our findings suggest
that a deficit in descending NAergic tone plays an important role in
Figure 4. Nerve-injured animals exhibit a preference for intrathecal but not
systemic reboxetine. In a conditioned place preference testing paradigm, the
tibial nerve transection (TNT) rats (unlike naive control rats) showed a significant
increase in the amount of time spent in the intrathecal reboxetine (10mg) paired
chamber after conditioning. However, both TNT and naive rats showed
a significant aversion to systemic reboxetine (30 mg/kg, i.p.) in the CPP
paradigm with a significant reduction in the amount of time spent in the
reboxetine-paired chamber after conditioning. Preference data shown as time
spent in reboxetine-paired chamber on test day—preconditioning day. Data
expressed as mean 6 SEM, n 5 7 per group (NS, not significant, *P , 0.05,
**P , 0.01; single sample, 2-tailed t tests).
Figure 5. Chronic intrathecal reboxetine does not prevent the development of
neuropathic sensitisation after discontinuation. After 2 weeks of twice daily
intrathecal reboxetine (10 mg) after tibial nerve transection (TNT), cessation of
reboxetine dosing caused sensitisation to return over the following week, with
significant mechanical sensitisation evident after 5 days (ie, by day 19). Data
are expressed as mean 6 SEM, n 5 5 per group. Comparisons between
reboxetine- and control saline-treated TNT rats over time were made using
2-way analysis of variance (ANOVA) with the Bonferroni post-test (***P ,
0.001). The presence of allodynia in either the reboxetine- or saline-treated
groups was determined over time by comparisons with pre-TNT baseline
thresholds or withdrawals using a repeated measures 1-way ANOVA with the
Dunnett multiple comparison test (##P , 0.01, ###P , 0.001).
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the expression of the neuropathic phenotype in terms of both tonic
ongoing and evoked neuropathic pain, and there is consequently
an imbalance between the descending inhibition and facilitation
that permits the behavioural expression of sensitisation.
In the same assay, systemic reboxetine was aversive (at a dose
that produced an equivalent degree of alleviation of mechanical
allodynia) in both TNT and naive rats. This may be because
systemic dosing of the reuptake inhibitor acts to enhance both
pro- and antinociceptive actions of the central NAergic system
(see Ref. 20) and therefore is relatively less effective against
ongoing pain than the intrathecal route. Alternatively, this aversive
action may indicate that the systemic side effects of this dose
outweigh any beneficial antiallodynic action. We also noted
during this testing that both of the higher doses of systemic
reboxetine seemed to be associated with behaviour change
suggestive of increased stress with more frequent urination and
defecation. These findings chime with clinical practice where
systemic dosing of NAergic reuptake inhibitors can be modestly
effective but is often compromised by side effects that result in
noncompliance with treatment.41
Given that the onset of ipsilateral sensitisation/allodynia after
tibial nerve injury coincides with a gradual reduction in
descending NAergic tone,24 we investigated the effect of
chronically dosing reboxetine on the development of allodynia.
The use of chronic systemicmonoamine reuptake inhibitors has
been shown to be more effective than acute in alleviating
sensitisation after nerve injury,10,13,31 and experience with
tricyclic antidepressants (TCAs) indicates that a period of 4 to 6
weeks’ dosing is usually necessary before beneficial effects are
seen.41 In this study, we found that chronic intrathecal dosing of
reboxetine given at the time of nerve injury and then twice daily
until day 15 after injury completely suppressed the development
of sensitisation after tibial nerve injury. The magnitude of the
beneficial effect was substantially greater than that seen with
single-shot dosing of reboxetine, suggesting a summating
therapeutic action (comparable to the effect of a maximal
intrathecal dose of the conopeptide Xen217436). Further
investigation will be required to determine whether this simply
represents accumulation of the drug in the intrathecal com-
partment (analogous to that reported for systemic dosing2) or
alternatively represents a form of NAergic (or downstream)
neuroplasticity in sensory circuits as has been suggested from
chronic systemic dosing studies with TCAs,1 perhaps involving
nerve growth factors such as BDNF.18
However, once reboxetine dosing ceased, allodynic sensitisa-
tion returned within a week to the same level as that seen in control
animals, suggesting that chronic reboxetine masks but does not
prevent the development of a neuropathic phenotype. This slow
development of sensitisation takes longer than would be expected
given the known pharmacokinetics of reboxetine—again suggest-
ing that there may be some longer-lasting plastic changes in the
sensory pathways. However, the 2-week time course of dosing
fails to prevent the subsequent induction of sensitisation possibly
becauseof underlyingpathological processes in other peripheral or
central nociceptive pathways. In particular, the intrathecal reuptake
inhibition approachwould not be expected to influence peripherally
generated afferent activity from nociceptors,10 which has been
shown to be present for several weeks after nerve injury and may
play a role in re-establishing central sensitisation.34,40 Similar
findings have been reported with systemic dosing of TCAs where
mechanical allodynia persisted after the cessation of dosing
althoughothermeasures of evoked sensitisationwere attenuated.1
It is conceivable that continuation of intrathecal dosing beyond the
period of altered peripheral afferent input could prevent the
subsequent development of sensitisation although this may also
require that aberrant afferent barrages from the periphery have
ceased in the meanwhile.34,40
The use of systemic monoamine reuptake inhibitors is
established as a therapeutic strategy for chronic pain in general
and neuropathic pain in particular.4,41 Animal studies have
shown that such systemic dosing increases NA levels in the
spinal cord.35 This raises the possibility that chronic intrathecal
dosing of a reuptake inhibitor could have therapeutic advan-
tages with an improved side effect profile. This must be set
against the substantial cost and logistical challenges of chronic
intrathecal delivery of drug in humans. This strategy has been
implemented for clonidine infusions for neuropathic and cancer
pain17 albeit complicated by postural hypotension, sedation,
and bradycardia. Such side effects might be minimised by
substitution of a reuptake inhibitor to augment the profile of
physiologically released noradrenaline at a spinal level. Few of
the selective reuptake inhibitors have had any spinal toxicity
testing,12 and it is relevant to note that toxicity concerns have
been raised after intrathecal administration of amitriptyli-
ne—possibly because of its off-target actions at the NMDA
receptor.51 However, the Xen2174 conus compound has been
reported as being safe for intrathecal administration in
humans.30 There may be a role for such strategies in the
treatment of severe neuropathic pain.
In summary, this study has shown a beneficial effect of spinal
NA-uptake inhibition on the development of the neuropathic
phenotype after peripheral nerve injury. Intrathecal reboxetine
alleviated both evoked and ongoing neuropathic pain, whereas
systemic administration caused an aversive response in both
naive and nerve-injured rats, indicating that selective spinal
administration may confer therapeutic benefits by restoring the
balance of descending pain modulation.
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